These data are corroborated in PD patients, who, when treated with the GLP-1 receptor agonist exenatide, demonstrate improvements in motor function that are sustained beyond the treatment period (Athauda et al., 2017, 2018, 2019). Here, GLP1R is linked to Parkinson disease.